In clinical practice, the combination with SGLT2 inhibitors appears not only safe but mechanistically synergistic, addressing both hemodynamic load and myocardial fibrosis without amplifying adverse events. The gene discussed is SLC5A2; the disease is Myocardial fibrosis.